Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma

Gan, Hui-Li; Chen, Longzhou; Xuemei, Sui; Wu, Bian; Zou, Shoupin; Li, Amin; Zhang, Yinci; Liu, Xueke; Wang, Danli; Cai, Shuyu; Liu, Xinkuang; Liang, Yong; Tang, Xiaolong

doi:10.1016/j.msec.2018.05.011

Cited by 44 publications

(22 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Polymer nanoparticles (NPs), one of the most promising and ideal drug carriers, acts as a continuous, detoxified, controlled release and targeted drug delivery system to significantly improve drug treatment and reduce toxic side effects [14,15]. Polymer nanocarriers with a diameter of 80-200 nm can avoid rapid renal clearance and recognition of the reticuloendothelial system (RES) in the liver, spleen, and lung; moreover, the 100-180-nm carrier has enhanced permeability and retention (EPR).…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

Tang

Xie

et al. 2020

Nanoscale Res Lett

Self Cite

View full text Add to dashboard Cite

Polymer materials encapsulating drugs have broad prospects for drug delivery. We evaluated the effectiveness of polyethylene glycol-poly (lactic-co-glycolic acid) (PLGA-PEG) encapsulation and release characteristics of PI3K/mTOR inhibitor NVP-BEZ235 (BEZ235). We proposed a strategy for targeting radiosensitization of liver cancer cells. The biocompatibility, cell interaction, and internalization of Glypican-3 (GPC3) antibody-modified, BEZ235-loaded PLGA-PEG nanoparticles (NP-BEZ235-Ab) in hepatoma cells in vitro were studied. Also, the cell killing effect of NP-BEZ235-Ab combined with γ-ray cell was evaluated. We used confocal microscopy to monitor nanoparticle-cell interactions and cellular uptake, conducted focus-formation experiments to analyze the synergistic biological effects of NP-BEZ235-Ab and priming, and studied synergy in liver cancer cells using molecular biological methods such as western blotting. We found that PLGA-PEG has good loading efficiency for BEZ235 and high selectivity to GPC3-positive HepG2 liver cancer cells, thus documenting that NP-BEZ235-Ab acts as a small-molecule drug delivery nanocarrier. At the nominal concentration, the NP-BEZ235-Ab nanoformulation synergistically kills liver cancer cells with significantly higher efficiency than does the free drug. Thus, NP-BEZ235-Ab is a potential radiosensitizer.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

Tang

Xie

et al. 2020

Nanoscale Res Lett

Self Cite

View full text Add to dashboard Cite

show abstract

“…25 Recently, nanoparticles with encapsulated therapeutic compounds have started playing an important role in anticancer research as they can passively accumulate in malignant lesions due to the enhanced permeability and retention effect. 26,27 Among these particles, gas-filled NBs are widely used as delivery vectors for sonosensitizers because of their good biocompatibility. 28,29 The IR820 NBs prepared in this study had spherical shapes with an average particle size of 545.5±93.1 nm ( Figure 1D).…”

Section: Discussionmentioning

confidence: 99%

Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma

Yang¹,

Jing²,

Han³

et al. 2021

DDDT

View full text Add to dashboard Cite

Purpose: Sonodynamic therapy (SDT) is considered a promising therapeutic strategy for the effective elimination of cancer cells. However, developing novel sonosensitizers with potentially high SDT efficacy remains a considerable challenge. Herein, we utilized near-infrared dye IR820 nanobubbles (NBs) combined with a dual PI3K/mTOR inhibitor PI-103 for the SDT treatment of hepatocellular carcinoma (HCC) in vitro. Methods: The generated reactive oxygen species (ROS) were quantified using 2,7-dichlorodihydrofluorescein diacetate to determine the feasibility of using IR820 NBs as a potential sonosensitizer. The inhibition effects of the synergistic therapy was examined using the cell counting Kit 8 assay and apoptosis assay. JC-1 staining was performed to study mitochondrial membrane depolarization, and the transwell assay was used for cell migration analysis. Results: The particle size and zeta potential of IR820 NBs were 545.5±93.1 nm and −5.19 ±1.73 mV, respectively. ROS accumulation was observed after HepG2 cells were treated with IR820 NBs under ultrasound irradiation. The SDT combined with PI-103 group inhibited cell viability and migration more strongly than the other groups (P < 0.01). The apoptosis assay also demonstrated a relatively high anti-HCC efficacy with the synergistic therapy, while JC-1 staining showed a decrease in the mitochondrial membrane potential after the combined treatment. Conclusion: The combination of SDT and PI-103 was very effective in suppressing HCC proliferation, which might help develop new minimally invasive cancer treatment strategies.

show abstract

“…The Sfb release profiles from the three formulations: ms‐Sfb‐3e, ms‐Sfb‐3d, and ms‐Sfb‐10d, respectively, were determined in citrate buffer solution pH 5, to simulate the tumoral acidic medium and in PBS of pH 7.4 to simulate physiological medium, using the dialysis method . The study was performed at 37°C, under slow vortex at 100 rpm.…”

Section: Methodsmentioning

confidence: 99%

Bovine serum albumin gel/polyelectrolyte complex of hyaluronic acid and chitosan based microcarriers for Sorafenib targeted delivery

Paşcalău

Tertiş

Páll

et al. 2020

J of Applied Polymer Sci

View full text Add to dashboard Cite

The development of systems for targeted delivery of Sorafenib in unresectable hepatocellular carcinoma to reduce the systemic toxicity is a challenge. In our article, we successfully prepared core‐shell microcapsules based on bovine serum albumin gel with polyelectrolyte complex multilayer shell of polysaccharides with opposite charges, hyaluronic acid, and chitosan, encapsulating Sorafenib, as targeting delivery system for improved hepatocellular carcinoma therapy. A bovine serum albumin gel core was formed by a method based on a sacrificial CaCO3 template, followed by the multilayer shell build‐up of Ca2+ cross‐linked hyaluronic acid hydrogel, and subsequently alternating multilayers of the polyelectrolyte complex formed between hyaluronic acid and chitosan. The following techniques: Fourier‐transform infrared and UV–Vis spectroscopy, X‐ray diffraction, differential scanning calorimetry, confocal laser scanning microscopy, atomic force microscopy, and scanning electron microscopy were used for the physicochemical characterization. These tests revealed the spherical shape of core‐shell type, the micro‐size, as well as the composition of microcapsules after their synthesis and proved the successful encapsulation and release of the drug. The promising results regarding encapsulation efficiency, Sorafenib release profile and cytotoxicity on HepG2 and mesenchymal stem cells, recommend Sorafenib loaded microcapsules as suitable targeted drug carriers for further in vivo studies for hepatocellular carcinoma therapy.

show abstract

Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma

Cited by 44 publications

References 37 publications

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

RETRACTED ARTICLE: The PI3K/mTOR dual inhibitor BEZ235 nanoparticles improve radiosensitization of hepatoma cells through apoptosis and regulation DNA repair pathway

Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular Carcinoma

Bovine serum albumin gel/polyelectrolyte complex of hyaluronic acid and chitosan based microcarriers for Sorafenib targeted delivery

Contact Info

Product

Resources

About